CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
滤泡性淋巴瘤 CD19 靶向治疗的最新进展
英文原题：Recent developments in CD19-targeted therapies for follicular lymphoma.
查看英文原题
Recent developments in CD19-targeted therapies for follicular lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
CD19 是滤泡性淋巴瘤治疗开发中一个有吸引力的靶点。鉴于其有效性，它将继续作为该疾病的一种有前景的疗法向前推进。
研究思路结论见上方概要
背景
CD19已成为滤泡性淋巴瘤中一个重要且新颖的治疗靶点。针对CD19的疗法，包括单克隆抗体、双特异性抗体和CAR-T 细胞疗法，为治疗滤泡性淋巴瘤和改善预后提供了有前景的途径。涵盖领域：我们综述了在滤泡性淋巴瘤中靶向CD19的作用和原理，以及不同的CD19靶向干预措施，如细胞疗法、双特异性抗体、抗体-药物偶联物和单克隆抗体。我们最后讨论了这些疗法可能如何影响滤泡性淋巴瘤的治疗格局。
展开英文摘要原文
INTRODUCTION: CD19 has emerged as an important and novel therapeutic target in follicular lymphoma. CD19-directed therapies, including monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies, offer promising avenues for treating follicular lymphoma and improving outcomes. AREAS COVERED: We review the role and rationale of targeting CD19 in follicular lymphoma and different interventions of CD19 targeting, such as cell therapy, bispecific antibodies, antibody-drug conjugates, and monoclonal antibodies.
We finalize with a discussion on how these therapies may influence the treatment landscape of follicular lymphoma. EXPERT OPINION: CD19 is an attractive target for therapeutic development in follicular lymphoma. Given its effectiveness, it will continue to move forward as a promising therapy for this disease.
论文信息
- 作者
- Saha A、Chavez JC
- 第一作者单位
- Department of Medicine/Hematology Oncology, University of South Florida, Tampa, FL, USA.United States
- 通讯作者单位
- Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.United States
- 文献类型
- 综述
- 期刊
- Expert opinion on biological therapy2024 Oct
- 原文标识
- PubMed 39291554 · DOI 10.1080/14712598.2024.2404100